Tumor-associated antigen peptide-Major Histocompatibility Complex (TAA-pMHC)

Tumor-associated antigens (TAAs) presented as peptide-MHC (pMHC) complexes are essential targets for modern cancer immunotherapy, serving as the primary interface for T-cell recognition of malignant cells (Source: Nature Reviews Immunology, 2019). These complexes are formed when intracellular proteins are degraded by the proteasome into short peptides, which are then loaded onto Major Histocompatibility Complex (MHC) molecules and transported to the cell surface. This mechanism allows the immune system to monitor the internal state of the cell, enabling the detection of mutated neoantigens, overexpressed self-antigens, or lineage-specific proteins that are not otherwise accessible on the cell surface (Source: Journal for ImmunoTherapy of Cancer, 2020). Therapeutic interventions such as T-cell receptor (TCR) engineered T-cells and TCR-mimetic bispecific antibodies are specifically designed to bind these pMHC targets with high affinity and specificity. Because pMHC complexes are highly specific to both the peptide sequence and the patient's Human Leukocyte Antigen (HLA) type, they offer a pathway to highly personalized and precise cancer treatment (Source: FDA Approval Summary for Kimmtrak, 2022). However, the effectiveness of targeting pMHC is often limited by the heterogeneity of antigen expression and the potential for tumors to downregulate MHC molecules to evade immune detection. Furthermore, the risk of off-target toxicity remains a significant concern, as therapeutic TCRs must be rigorously screened to avoid cross-reactivity with similar peptides presented on healthy tissues (Source: Journal of Hematology & Oncology, 2023). Despite these challenges, pMHC-targeted therapies represent a transformative approach for treating solid tumors that lack traditional surface-bound targets, expanding the range of druggable intracellular proteins (Source: FDA Approval Summary for Tecelra, 2024).

Other names

pMHCPeptide-HLA complexMHC-restricted antigenTumor-specific peptide-MHCNeoantigen-MHC complexHLA-peptide complex

Therapeutic agents bind to the specific peptide-MHC complex on the tumor cell surface, facilitating the formation of an immunological synapse between the tumor cell and a T-cell, which leads to T-cell activation and subsequent tumor cell lysis (Source: Nature Reviews Drug Discovery, 2021).